South Korea Women’s Health Market Size & Outlook
South Korea women’s health market, 2018-2030 (US$M)
Related Markets
South Korea women’s health market highlights
- The South Korea women’s health market generated a revenue of USD 732.6 million in 2023 and is expected to reach USD 1,296.6 million by 2030.
- The South Korea market is expected to grow at a CAGR of 8.5% from 2024 to 2030.
- In terms of segment, contraceptives was the largest revenue generating application in 2023.
- Endometriosis & Uterine Fibroids is the most lucrative application segment registering the fastest growth during the forecast period.
Women’s health market data book summary
| Market revenue in 2023 | USD 732.6 million |
| Market revenue in 2030 | USD 1,296.6 million |
| Growth rate | 8.5% (CAGR from 2023 to 2030) |
| Largest segment | Contraceptives |
| Fastest growing segment | Endometriosis & Uterine Fibroids |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Hormonal Infertility, Contraceptives, Postmenopausal Osteoporosis, Endometriosis & Uterine Fibroids, Menopause, Polycystic Ovary Syndrome (PCOS) |
| Key market players worldwide | AbbVie Inc, Bayer AG, Merck & Co Inc, Pfizer Inc, Teva Pharmaceutical Industries Ltd, Agile Therapeutics Inc, Amgen Inc, Apothecus, Blairex Laboratories, Ferring |
Other key industry trends
- In terms of revenue, South Korea accounted for 1.7% of the global women’s health market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, Japan women’s health market is projected to lead the regional market in terms of revenue in 2030.
- China is the fastest growing regional market in Asia Pacific and is projected to reach USD 3,966.1 million by 2030.
Contraceptives was the largest segment with a revenue share of 29.25% in 2023. Horizon Databook has segmented the South Korea women’s health market based on hormonal infertility, contraceptives, postmenopausal osteoporosis, endometriosis & uterine fibroids, menopause, polycystic ovary syndrome (pcos) covering the revenue growth of each sub-segment from 2018 to 2030.
The increasing prevalence of target diseases, high awareness, and well-established healthcare structure are some of the key factors driving the market in South Korea. The prevalence of osteoporosis in Korean adults aged 50 or above was 35.5% in women and 7.5% in men.
The estimated osteoporosis diagnosis rate was 26.2% (men 5.8% & women 29.9%) and the treatment rate was 12.8%. Global and local pharmaceutical companies and research organizations are adopting different market strategies to improve women’s health in South Korea.
For instance, in June 2020, Daewon Pharmaceutical launched the teriparatide biosimilar Terrosa used for the treatment of osteoporosis in postmenopausal women. Similarly, in December 2023, Zydus Lifesciences Ltd.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Women’s Health Market Scope
Women’s Health Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
South Korea women’s health market size, by application, 2018-2030 (US$M)
South Korea Women’s Health Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
